Recruiting NCT03925701
Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Vildagliptin, vildagliptin\metformin.
- Who it may be relevant to
- Registry conditions: dm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM
Overview
Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.
Detailed description
Clinical study evaluating vildagliptin versus vildagliptin/metformin on nonalcoholic fatty liver disease with DM.
Interventions
- Drug Vildagliptin
vildagliptin twice daily - Drug vildagliptin\metformin
vildagliptin\\metformin twice daily
Primary outcome measures
- number of patients with improved nafld and insulin resistance [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- NAFLD and type 2 DM
Exclusion criteria
- Viral hepatitis.
- Child score more than 6.
- renal impairment.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT03925701 · diabetes mellitus tanta